Seegene and BD Form Worldwide Collaboration to Develop Multiplex Molecular Diagnostic Assays

Sep 14, 2015

SEOUL, KOREA and BALTIMORE, MD, Sept. 14, 2015 – Seegene Inc. (096530.KQ) and BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that they have entered into a worldwide collaboration agreement to co-develop multiplex real-time PCR reagents for the BD MAX System.

Under the terms of the agreement, Seegene will develop and manufacture multiplex tests based on novel DPO, TOCE and MuDT technologies designed exclusively for BD’s molecular diagnostics platform. BD, in turn, will have worldwide commercialization rights to these tests.

“We are very pleased to partner with Seegene and incorporate their innovative proprietary technologies into our easy-to-use, fully automated BD MAX platform,” said Doug White, VP/GM Molecular Diagnostics and Women’s Health, BD Life Sciences. “With Seegene’s multiplex reagents that simultaneously detect and identify various types of pathogens in a single test, we will continue to expand the BD MAX assay portfolio.”

The BD MAX System offers an efficient path to improved clinical outcomes by combining and automating real-time PCR extraction, amplification and detection into a single platform capable of running a wide range of assays across multiple disease states, enabling physicians to address a wide breadth of testing needs.

Seegene’s CEO, Dr. Jong-Yoon Chun, added, “Our agreement with BD represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market. BD's commercial strength in the IVD market will help to bring Seegene’s powerful multiplex PCR chemistry technologies to more physicians and patients worldwide.”

About Seegene

Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies – ACP, DPO, READ, TOCE, and MuDT - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. 

For more information on BD, please visit bd.com.

CareFusion Corporation

Troy Kirkpatrick

858 617 2361
Email Troy

Back to News Releases